| Literature DB >> 36244850 |
Archana Keche1, Sharmistha Chakravarty2, Shagufta Khatoon3, Pankaj Kannauje4, Ripu Daman Arora5.
Abstract
A case of Acanthamoeba rhinorrhea in a 32 years female, who was recently recovered from COVID-19 infectionat a tertiary care institute in India. Though, there was no standard treatment protocol for management of amoebic-meningo encephalitis. The patient was managed successfully with combination therapy of amphotericin B and miltefosine. Agents having trophicidal and cysticidal activities are used for treatment of CNS Acanthamoeba infection. COVID 19 infection, steroid therapy anddiabetes mellitus which lead to low immunitywere found to be associated contributing factors.Entities:
Keywords: Acanthamoeba; COVID19; Rhinorrhea
Year: 2022 PMID: 36244850 PMCID: PMC9561446 DOI: 10.1016/j.ijmmb.2022.09.014
Source DB: PubMed Journal: Indian J Med Microbiol ISSN: 0255-0857 Impact factor: 1.347
Fig. 1A) Trophozoite of Acanthamoeba in wet mount from culture. B) Geimsa stain of Acanthamoeba C) Wet mount examination of culture with methylene blue drop.